Source comparison
Mechanism of Action: Upstream vs Downstream IGF-1 Pathway Activation
Human growth hormone binds to GH receptors on hepatocytes, triggering JAK2-STAT5 signaling that upregulates IGF-1 gene transcription. The liver then synthesizes and secretes IGF-1 into systemic circulation, where it binds to IGF-binding proteins (IGFBPs) that
This comparison does not assign a generated winner or score.
- Human growth hormone binds to GH receptors on hepatocytes, triggering JAK2-STAT5 signaling that upregulates IGF-1 gene transcription. The liver then synthesizes and secretes IGF-1 into systemic circulation, where it binds to IGF-binding proteins (IGFBPs) that modulate its half-life and tissue delivery. Circulating IGF-1 eventually reaches target tissues. Skeletal muscle, cartilage, bone. And activates IGF-1 receptors (IGF-1R) that initiate PI3K/Akt and MAPK/ERK pathways driving protein synthesis, cell proliferation, and glucose uptake. The entire cascade from HGH injection to peak tissue-level IGF-1 receptor activation takes 48–72 hours, with serum IGF-1 levels peaking at 12–24 hours post-injection but functional anabolic signaling lagging behind due to IGFBP kinetics.
- IGF-1 LR3 skips the upstream steps entirely. The arginine substitution at position 3 reduces binding affinity to IGFBPs by approximately 90%, while the 13-amino-acid N-terminal extension further stabilizes the molecule against enzymatic degradation. The result: IGF-1 LR3 circulates in free, bioactive form with a half-life of 20–24 hours. More than 100 times longer than endogenous IGF-1. It reaches tissue IGF-1 receptors within 4–6 hours of subcutaneous injection and activates the same PI3K/Akt and MAPK/ERK pathways that endogenous IGF-1 would activate, but without requiring liver synthesis or waiting for IGFBP dissociation. Researchers studying acute anabolic signaling windows use IGF-1 LR3 because the compound's action is immediate and dose-proportional. Injecting 100 mcg delivers predictable receptor occupancy within hours, not days.
- Our experience with both compounds in controlled protocols shows this: HGH is the tool when systemic IGF-1 elevation matters. Studies examining liver IGF-1 synthesis capacity, GH receptor function, or multi-tissue coordinated growth. IGF-1 LR3 is the tool when direct receptor activation matters. Studies isolating IGF-1R signaling from GH-mediated effects, testing tissue-specific anabolic responses, or requiring rapid-onset experimental windows.